METUPUK joins the Northern Ireland Cancer Charities Coalition

METUPUK has joined the Northern Ireland Coalition (NICCC) and will work collaboratively with partner charities to improve outcomes for cancer patients in Northern Ireland. Ann McBrien, METUPUK’s Northern Ireland Executive

Data collection for metastatic breast cancer, “we are only counted when we are dead” – Kat Southwell

Just shy of six years ago I was diagnosed with Inflammatory Breast Cancer (IBC). Rare with a “high fatality rate and difficult to treat” is what I learnt in the

Drugs drugs everywhere, can you access ones that work? Kirstin Spencer

Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge

METUPUK at the UK Interdisciplinary Breast Cancer Symposium

METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a

NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib

METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with

On the trail of a Clinical Trial…

On the trail of a Clinical Trial…

METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and

Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?

And where do patients start when looking for a metastatic trial themselves?

METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.

METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)

Philippa Hetherington Remembered

We had to confirm back on the 5th November the heartbreaking news that the wonderful Philippa Hetherington had died 💔

She was an absolute force of intellectual nature for breast cancer in general, not just Inflammatory Breast Cancer.

Did you know that the Trodelvy campaign in England for TNBC was HER campaign?

Trodelvy Now! Latest Update

Trodelvy Approved by NICE

METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.